دورية أكاديمية
أعرض في EDS

Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients.

التفاصيل البيبلوغرافية
العنوان: Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients.
المؤلفون: Hauber H; Meakins-Christie Laboratories, McGill University, Montreal, Canada., Taha R, Bergeron C, Migounov V, Hamid Q, Olivenstein R
المصدر: Canadian respiratory journal [Can Respir J] 2006 Mar; Vol. 13 (2), pp. 73-8.
نوع المنشور: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Hindawi Publishing Corporation Country of Publication: Egypt NLM ID: 9433332 Publication Model: Print Cited Medium: Print ISSN: 1198-2241 (Print) Linking ISSN: 11982241 NLM ISO Abbreviation: Can Respir J Subsets: MEDLINE
أسماء مطبوعة: Publication: <2015- > : Cairo : Hindawi Publishing Corporation
Original Publication: Oakville, Ont. : Pulsus Group Inc., 1994-
مواضيع طبية MeSH: Adrenal Cortex Hormones/*therapeutic use , Aerosol Propellants/*therapeutic use , Anti-Asthmatic Agents/*therapeutic use , Asthma/*drug therapy , Beclomethasone/*therapeutic use , Budesonide/*therapeutic use , Hydrocarbons, Fluorinated/*therapeutic use, Administration, Inhalation ; Algorithms ; Biomarkers ; Cytokines/analysis ; Double-Blind Method ; Eosinophils/pathology ; Female ; Humans ; Lymphocytes ; Male ; Powders/therapeutic use ; Sputum/cytology
مستخلص: Background: Inhaled corticosteroids are powerful drugs that can suppress airway inflammation in asthmatic patients. Deposition of most of the inhaled corticosteroid occurs mainly in the central airways. However, a new hydrofluoroalkane formulation of beclomethasone dipropionate (HFA-BDP) is preferentially deposited in the distal airways. Inflammatory characteristics of induced sputum have been shown to differ in samples collected early after sputum induction compared with later.
Objective: To compare the effects of HFA-BDP and budesonide in a dry powder inhaler (DPI-BUD) on inflammatory cells and inflammatory cytokine expression in early and late induced sputa compared with placebo.
Methods: Seventeen patients with mild, intermittent bronchial asthma were randomly assigned to two treatment groups: eight patients received HFA-BDP and nine patients received DPI-BUD. Each patient was treated with one of the active treatments and placebo (for four weeks), with a two-week washout interval in between. Inflammatory cells and expression of interleukin (IL)-4 and IL-5 were measured in early and late induced sputa before and after active treatment, as well as before and after placebo treatment using immunocytochemistry and in situ hybridization.
Results: Compared with placebo, eosinophils were significantly reduced in both early and late induced sputa after HFA-BDP treatment (P<0.05), whereas DPI-BUD had a significant effect only on early induced sputum. Both HFA-BDP and DPI-BUD decreased IL-4 expression in early and late induced sputa, but the effect was more prominent with HFA-BDP. IL-5 expression was reduced in both early and late induced sputa after HFA-BDP treatment. DPI-BUD significantly decreased IL-5 expression in early but not in late induced sputum. The number of lymphocytes was not altered by either treatment.
Conclusions: HFA-BDP reduced eosinophilic inflammation and T helper 2-type cytokine expression in both early and late induced sputa, whereas the effect of DPI-BUD on inflammation was predominantly demonstrated in early induced sputum.
References: Eur Respir J. 1992 Jan;5(1):73-9. (PMID: 1577153)
Am Rev Respir Dis. 1992 Mar;145(3):669-74. (PMID: 1546849)
J Aerosol Med. 1994;7(Suppl 1):S49-53. (PMID: 10147081)
J Immunol. 1995 May 1;154(9):4719-25. (PMID: 7722324)
Am J Respir Crit Care Med. 1995 Jul;152(1):45-52. (PMID: 7599861)
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17. (PMID: 8756799)
Eur Respir J. 1997 Jul;10(7):1496-9. (PMID: 9230236)
J Allergy Clin Immunol. 1997 Jul;100(1):44-51. (PMID: 9257786)
J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):238-45. (PMID: 9949314)
Chest. 1999 Feb;115(2):343-51. (PMID: 10027430)
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):322-8. (PMID: 10452752)
Clin Exp Allergy. 1999 Oct;29(10):1356-66. (PMID: 10520056)
J Allergy Clin Immunol. 2005 Feb;115(2):280-6. (PMID: 15696082)
J Allergy Clin Immunol. 1999 Dec;104(6):1215-22. (PMID: 10589004)
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1308-13. (PMID: 11029336)
Int J Clin Pract. 2001 Mar;55(2):100-6. (PMID: 11321849)
Am J Respir Crit Care Med. 2001 May;163(6):1470-5. (PMID: 11371420)
Respir Med. 2001 Sep;95(9):720-7. (PMID: 11575892)
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1964-70. (PMID: 11734453)
Chest. 2002 Aug;122(2):510-6. (PMID: 12171824)
J Allergy Clin Immunol. 2003 Jul;112(1):58-63. (PMID: 12847480)
Can Respir J. 2004 Mar;11(2):146-50. (PMID: 15045046)
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6760-4. (PMID: 2958847)
Lancet. 1993 Dec 18-25;342(8886-8887):1510-3. (PMID: 7504773)
المشرفين على المادة: 0 (Adrenal Cortex Hormones)
0 (Aerosol Propellants)
0 (Anti-Asthmatic Agents)
0 (Biomarkers)
0 (Cytokines)
0 (Hydrocarbons, Fluorinated)
0 (Powders)
51333-22-3 (Budesonide)
KGZ1SLC28Z (Beclomethasone)
R40P36GDK6 (apaflurane)
تواريخ الأحداث: Date Created: 20060322 Date Completed: 20060929 Latest Revision: 20181113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC2539014
DOI: 10.1155/2006/648392
PMID: 16550263
قاعدة البيانات: MEDLINE
الوصف
تدمد:1198-2241
DOI:10.1155/2006/648392